VVP
TXMD icon

Venture Visionary Partners’s TherapeuticsMD TXMD Stock Holding History

Venture Visionary Partners’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-53
Closed -$527 – 1462
2022
Q2 		$527 Buy
+53
New +$506 ﹤0.01% 1646

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Venture Visionary Partners's TXMD Position: Q3 2022 in Review

Venture Visionary Partners sold out of TherapeuticsMD (TXMD) in Q3 2022, closing a stake of 53 shares — an estimated $527 sold.

Venture Visionary Partners first reported a position in TXMD in Q2 2022 and held it in 1 quarter. The position peaked at $527 in Q2 2022. 43 funds tracked by Wall St. Rank hold TXMD as of Q3 2022.

  • Venture Visionary Partners reported no remaining TherapeuticsMD position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 53 TherapeuticsMD shares in Q3 2022, an estimated $527.
  • Venture Visionary Partners first reported a position in TherapeuticsMD in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's TherapeuticsMD position peaked at $527 in Q2 2022.
  • 43 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.